In addition, it is IM administered which requires a doctor/clinic visit and much more painful. Plus leronlimab has a better safety profile than any of the competition.....ViiV, Gilead, etc.
It may take some time and/or education of doctors and patients but there is little doubt that combo will be successful and gain much of the MDR2+ market share.
(2)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.